Back Daily Mail Experimental cancer drug that targets common genetic fault can shrink tumours by 64% in six weeks
Search Sections 21 Nov
Close
Advertisement
Experimental cancer drug that targets common genetic fault can shrink tumours by 64% in six weeks30 Oct 4:49pm

Experimental cancer drug that targets common genetic fault can shrink tumours by 64% in six weeks

Daily Mail
The drug AMG 510 was tested on four lung cancer patients. Two patients saw their tumours reduce, according to the pharmaceutical giant Amgen Research, California.
Read full story
 Like Comment
Advertisement

Comments

No comments yet...
On the top

Date settings

Today is Thursday, November 21, 2019

+ 1 -
+ 1 -
+ 2016 -

Close

By using our website, you agree to the use of cookies as described in our cookie policy.

Accept

Daily Mail

Close